Company intelligence / Profile preview

Invenux, LLC

Windsor or Denver area*, Colorado, United States

Ownership: Private
Development stage: Other

Overview

Invenux’s lead candidate, SCD‑101—a botanical extract—has completed dose-escalation and crossover studies involving 50 patients with sickle cell disease. The studies demonstrated safety and clinical benefit but highlighted a need to improve potency due to high pill burden. The company is working on reformulation efforts. IND approval has been achieved for this program.[2][3]

Therapeutic areas: HematologyRare Diseases
Modalities: Botanical extract (SCD-101)Small molecule drug[2][3]
Industry: Biotech

Drug pipeline

1 asset

SCD-101

Partnerships

Academic collaborations with Rutgers University and The Children’s Hospital of Philadelphia; clinical trial collaboration with Kings County Hospital Adult Sickle Program in New York.[2]

Beyond the preview

Go deeper on Invenux, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invenux, LLC.